At the last check on Thursday, Heron Therapeutics Inc.’s (NASDAQ:HRTX) stock was down -$0.04, moving down -2.07 percent to $1.65. The average number of shares traded per day over the past five days has been 776,203 shares. 1 time new highs have been achieved over the past 5 days, with a -$0.0350 fall in that time frame. In the last twenty days, the average volume was 2,112,431, while in the previous 50 days, it was 2,006,888.
Since last month, HRTX stock rose 7.47%. Shares of the company fell to $1.3600 on 08/15/23, the lowest level in the past month. A 52-week high of $5.10 was reached on 01/18/23 after having rallying from a 52-week low of $1.07. Since the beginning of this year, HRTX’s stock price has dropped by -33.80% or -$0.8550, and marked a new high 7 times. However, the stock has declined by -67.55% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
HRTX stock investors should be aware that Heron Therapeutics Inc. (HRTX) stock had its last reported insider trading activity 41 days ago on Jul 21. Morgan Adam, the Director of the company, purchased of 2,486,744 shares for $1.37 on Jul 21. It resulted in a $3,406,839 investment by the insider.
Financial Health
In the three months ended June 29, Heron Therapeutics Inc.’s quick ratio stood at 1.40, while its current ratio was 1.90, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 45.40% percent. Based on annual data, HRTX earned $52.8 million in gross profit and brought in $107.67 million in revenue.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. HRTX’s revenue rose 13.0% to $29.62 million during the quarter, while net income inched up to $31.76 million. While analysts expected Heron Therapeutics Inc. to report -$0.23 quarterly earnings, the actual figure was -$0.35 per share, beating the consensus estimate by -52.20%. During the quarter, the company generated -$41.97 million in EBITDA. The liabilities of Heron Therapeutics Inc. were 240.51 million at the end of its most recent quarter ended June 29, and its total debt was $156.12 million. The value of shareholders’ equity is $140.76 million.
Technical Picture
This quick technical analysis looks at Heron Therapeutics Inc.’s (HRTX) price momentum. With a historical volatility rate of 45.99%, the RSI 9-day stood at 49.33% on 30 August.
With respect to its five-day moving average, the current Heron Therapeutics Inc. price is down by -2.08% percent or -$0.0350. At present, HRTX shares trade +1.54% above its 20-day simple moving average and -32.02% percent below its 100-day simple moving average. However, the stock is currently trading approximately +35.95% above its SMA50 and -52.18% below its SMA200.
Stochastic coefficient K was 66.63% and Stochastic coefficient D was 63.63%, while ATR was 0.1081. Given the Stochastic reading of 66.28% for the 14-day period, the RSI (14) reading has been calculated as 52.03%. As of today, the MACD Oscillator reading stands at -0.0156.
Analyst Ratings
Guggenheim launched its rating on Heron Therapeutics Inc. (NASDAQ: HRTX) to a Buy in a note to investors on May 27, 2020. Heron Therapeutics Inc. (HRTX) has been rated Buy by analysts. According to 0 brokerage firms, HRTX is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Heron Therapeutics Inc. stock as buy, with 6 recommending it as overweight.
With a median target price of $8.00, the current consensus forecast for the stock is $5.00 – $10.00. Based on these forecasts, analysts predict Heron Therapeutics Inc. (HRTX) will achieve an average price target of $7.75.
